Top Italian public health official faces allegation of failing to disclose pharma linksBMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k5325 (Published 17 December 2018) Cite this as: BMJ 2018;363:k5325
- Michael Day
The row over the conflicts of interests of one of Italy’s most senior public health officials has reignited, with fresh claims that he failed to disclose earnings from drug companies.
The country’s leading consumer rights group, Codacons, this week published what it said were all the relations between Walter Ricciardi, head of the National Institute of Health (Istituto Superiore di Sanita, ISS) and the drug industry.1
The group said that Ricciardi should be investigated for activities including the receipt of €4000 (£3600; $4500) for speaking to Pfizer staff in 2017, his involvement in a project sponsored by Pfizer and Janssen-Silage with the medicine faculty of Milan’s Catholic University of the Sacred Heart, a €400 sponsorship payment from GlaxoSmithKline in November 2017, and his role as “scientific director” in an Abbvie project that involved a payment of €58 250 to the Milan …